Literature DB >> 17502100

The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.

Derek E Piper1, Simon Jackson, Qiang Liu, William G Romanow, Susan Shetterly, Stephen T Thibault, Bei Shan, Nigel P C Walker.   

Abstract

Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be involved in the regulation of extracellular levels of the low-density lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not been shown to degrade the LDLR, and its LDLR-lowering mechanism remains uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the stable interaction between these domains prevents access to PCSK9's catalytic site. The C-terminal domain of PCSK9 has a novel protein fold and may mediate protein-protein interactions. The structure of PCSK9 provides insight into its biochemical characteristics and biological function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502100     DOI: 10.1016/j.str.2007.04.004

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  67 in total

1.  Kinetic dissection of the pre-existing conformational equilibrium in the trypsin fold.

Authors:  Austin D Vogt; Pradipta Chakraborty; Enrico Di Cera
Journal:  J Biol Chem       Date:  2015-07-27       Impact factor: 5.157

Review 2.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.

Authors:  Ashwin Durairaj; Alberto Sabates; Jonathan Nieves; Brian Moraes; Seth Baum
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08

Review 3.  Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers.

Authors:  Stephen C Blacklow
Journal:  Curr Opin Struct Biol       Date:  2007-09-17       Impact factor: 6.809

4.  PCSK9 function and physiology.

Authors:  Andrew S Peterson; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-07       Impact factor: 5.922

5.  Histone H4 promotes prothrombin autoactivation.

Authors:  Sergio Barranco-Medina; Nicola Pozzi; Austin D Vogt; Enrico Di Cera
Journal:  J Biol Chem       Date:  2013-10-30       Impact factor: 5.157

6.  PCSK9 function and physiology.

Authors:  Andrew S Peterson; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-03-28       Impact factor: 5.922

7.  The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain.

Authors:  Eric N Hampton; Mark W Knuth; Jun Li; Jennifer L Harris; Scott A Lesley; Glen Spraggon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-05       Impact factor: 11.205

8.  APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.

Authors:  Ting Fu; YangYang Guan; Junjie Xu; Yan Wang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-05-09       Impact factor: 4.698

9.  Isolation and characterization of the circulating truncated form of PCSK9.

Authors:  Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

10.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

Authors:  Joyce C Y Chan; Derek E Piper; Qiong Cao; Dongming Liu; Chadwick King; Wei Wang; Jie Tang; Qiang Liu; Jared Higbee; Zhen Xia; Yongmei Di; Susan Shetterly; Ziva Arimura; Heather Salomonis; William G Romanow; Stephen T Thibault; Richard Zhang; Ping Cao; Xiao-Ping Yang; Timothy Yu; Mei Lu; Marc W Retter; Gayle Kwon; Kirk Henne; Oscar Pan; Mei-Mei Tsai; Bryna Fuchslocher; Evelyn Yang; Lei Zhou; Ki Jeong Lee; Mark Daris; Jackie Sheng; Yan Wang; Wenyan D Shen; Wen-Chen Yeh; Maurice Emery; Nigel P C Walker; Bei Shan; Margrit Schwarz; Simon M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.